TY  - JOUR
A1  - Wernicke, Caroline M.
A1  - Grunewald, Thomas G. P.
A1  - Juenger, Hendrik
A1  - Kuçi, Selim
A1  - Kuçi, Zyrafete
A1  - Köhl, Ulrike
A1  - Mueller, Ingo
A1  - Döring, Michaela
A1  - Peters, Christina
A1  - Lawitschka, Anita
A1  - Kolb, Hans-Jochem
A1  - Bader, Peter
A1  - Burdach, Stefan
A1  - Teichert- von Lüttichau, Irene
T1  - Mesenchymal stromal cells for treatment of steroid-refractory GvHD : a review of the literature and two pediatric cases
T2  - International archives of medicine
N2  - Severe acute graft versus host disease (GvHD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation. Human mesenchymal stromal cells (MSCs) play an important role in endogenous tissue repair and possess strong immune-modulatory properties making them a promising tool for the treatment of steroid-refractory GvHD. To date, a few reports exist on the use of MSCs in treatment of GvHD in children indicating that children tend to respond better than adults, albeit with heterogeneous results. We here present a review of the literature and the clinical course of two instructive pediatric patients with acute steroid-refractory GvHD after haploidentical stem cell transplantation, which exemplify the beneficial effects of third-party transplanted MSCs in treatment of acute steroid-refractory GvHD. Moreover, we provide a meta-analysis of clinical studies addressing the outcome of patients with steroid-refractory GvHD and treatment with MSCs in adults and in children (n = 183; 122 adults, 61 children). Our meta-analysis demonstrates that the overall response-rate is high (73.8%) and confirms, for the first time, that children indeed respond better to treatment of GvHD with MSCs than adults (complete response 57.4% vs. 45.1%, respectively). These data emphasize the significance of this therapeutic approach especially in children and indicate that future prospective studies are needed to assess the reasons for the observed differential response-rates in pediatric and adult patients. Additional file 1: MSCs expansion and release criteria.his file contains a detailed description of the MSCs expansion and release criteria for Case A and Case B.
Y1  - 2011
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/22676
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30-112629
N1  - © 2011 Wernicke et al. ; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
VL  - 4
IS  - Art. 27
SP  - 1
EP  - 9
PB  - BioMed Central
CY  - London
ER  -